The Worldwide Cardiac Arrest Treatment Industry is Expected to Reach $27+ Billion by 2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Cardiac Arrest Treatment Market (2021-2026) by Treatment, Distribution Channel and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Cardiac Arrest Treatment Market is estimated to be USD 17.63 Bn in 2021 and is expected to reach USD 27.39 Bn by 2026, growing at a CAGR of 9.21%.

The major factor raising the global cardiac arrest treatment market is an increase in cardiovascular disorders (CVDs). The increasingly sedentary lifestyle, high alcohol & tobacco consumption, and rising geriatric population are leading to the increase in CVDs. Furthermore, increasing awareness of cardiac resynchronization therapy devices among the population is escalating the market growth. However, frequent product calls and the high cost of Treatment are anticipated to hinder the market during the forecast period.

Huge investments in research and development associated with cardiac arrest treatment are expected to foster new opportunities for the market during the forecast period.

The Global Cardiac Arrest Treatment Market is segmented based on Treatment, Distribution Channel and Geography.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Cardiac Arrest Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
• The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
• The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Market Dynamics

Drivers

• Increasing Burden of Cardiovascular Diseases
• Increase in Geriatric Population
• Growing Awareness of Generic Drugs and Minimal Invasive Procedures
• Favorable Reimbursement Policies

Restraints

• Expensive Treatment and Device Replacement Cost

Opportunities

• Technological Advancement
• Rising Healthcare Expenditure in Emerging Countries

Challenges

• Lack of Skilled Professionals
• Product Recalls

Companies Mentioned

• Abbott Laboratories
• Amgen Inc
• Allergan
• Bayer AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Bristol Myers Squibb Company
• Fukuda Denshi Co, Ltd
• Koninklijke Philips N.V.
• LivaNova PLC
• Lepu Medical
• MicroPort Scientific Corporation
• Medico S.p.A.
• Medtronic plc
• Novartis AG
• Neurescue
• Nihon Kohden Corporation
• Osypka Medical
• Pfizer Inc
• Sanofi S.A.
• Shree Pacetronix Ltd
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Stryker Corporation
• Viatris Inc
• ZOLL Medical Corporation

For more information about this report visit https://www.researchandmarkets.com/r/j1yxb5